Tissue Regenix Group (TRX)
02/11/2017 - 09:06 StockMarketWire
Tissue Regenix, a regenerative medical devices company, has appointed Steve Couldwell as chief executive officer of the gr...
02/11/2017 - 07:00 RNS
RNS Number: 3338V Tissue Regenix Group PLC 02 November 2017 Tissue Regenix Group plc Appointment of CEO Steve Couldwell appointed Group CEO Leeds, 02 November 2017 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company announces the appointment of Steve Couldwell, as Chief Executive Off...
18/10/2017 - 06:00 RNS
RNS Number: 8786T Tissue Regenix Group PLC 18 October 2017 [This announcement contains inside information.] Tissue Regenix Group plc Directorate Change Leeds, 18 October 2017 - The Board of Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "The Group") today announces that Antony Odell, Chief Executive Officer (CEO), will be stepping down fro...
11/10/2017 - 06:15 RNS
RNS Number: 2491T Tissue Regenix Group PLC 11 October 2017 Hardman Research: Dual revenue stream growth Dual revenue stream growth - TRX has a broad portfolio of regenerative medicine products developed from decellularised human and porcine soft tissues for the wound care, orthopaedics, and cardiac markets. Since the launch of DermaPure, focus has...
Join interactive investor
- £22.50 fixed quarterly charge includes £22.50 in trading credits
- £10 per trade or £6 for frequent traders
- No % platform fees
- £1 per trade for regular investment or dividend reinvestment